Treatment of IBD: Where We Are and Where We Are Going
- 1 January 2015
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 110 (1), 114-126
- https://doi.org/10.1038/ajg.2014.357
Abstract
In assessing the best evidence for optimizing management of inflammatory bowel disease (IBD), the focus is typically on anti-inflammatory agents and therapies that modulate the immune system. The intestinal immune response remains the key focus of developing therapies as well. In the past decade, the concept of dysbiosis of the gut microbiome has emerged as a potential pathogenetic focus in IBD, and with this a burgeoning interest in manipulating the microbiome as a means of controlling the disease has emerged. In this review, anti-inflammatory, immune-modulating, and microbiome-modulating therapies will be covered in terms of what is known today, as well as treatments that may be part of the therapeutic armamentarium in the near future. Concurrent with the evolution of our understanding of the basic biology of IBD, there is an increasing appreciation for the disconnect between patients' symptoms and inflammatory disease. As clinical trials have simultaneously addressed both symptom scores and mucosal healing, investigators and clinicians have gained a greater appreciation for the fact that many symptoms may not be driven by active inflammation, and hence focusing only on immunomodulatory therapies would not serve patients' needs fully. Furthermore, there is an emerging recognition of the importance of stress and psychological health in symptom experience and treatment needs. In this review, approaches to managing patients' symptoms as well as other adjunctive approaches to improving well-being will also be discussed. Finally, throughout this review, important research questions regarding different aspects of treatment will be proposed.Keywords
This publication has 94 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- Acupuncture and Moxibustion for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEvidence-Based Complementary and Alternative Medicine, 2013
- Metabolic Profiling of the Impact of Oligofructose-Enriched Inulin in Crohn's Disease Patients: A Double-Blinded Randomized Controlled TrialClinical and Translational Gastroenterology, 2013
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisThe New England Journal of Medicine, 2012
- Probiotics in the Management of Inflammatory Bowel DiseaseDrugs, 2012
- Common Symptoms and Stressors Among Individuals With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2011
- Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's diseaseGut, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Treatment of Crohn's Disease with 6-MercaptopurineThe New England Journal of Medicine, 1980